Slideshow

Osteoporosis: 3 Things to Know

Author(s):

Mark L. Fuerst

Drawbacks of bisphosphonate holidays, bone benefits of the Mediterranean diet, and a new weapon against glucocorticoid-induced osteoporosis.

References1. Bindon B, Adams W, Balasubramanian N, Sandhu J, Camacho P. Osteoporotic fractures during bisphosphonate drug holiday. Endocr Pract. 2018;24:163-169. doi: 10.4158/EP171975.OR.2. Silva TR, Martins CC, Spritzer PM. Mediterranean dietary pattern is positively associated with bone mineral density and lean mass in postmenopausal women: a cross-sectional study. Presented at: ENDO 2018; March 19, 2018; Chicago, Illinois. Abstract MON-301.3. Saag KG, Wagman RB, Geusens P, et al. Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study. Lancet Diabetes Endocrinol. 2018;6:445-454. doi: 10.1016/S2213-8587(18)30075-5.

Related Videos
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Laure Gossec, MD, PhD: Informing Physician Treatment Choices for Psoriatic Arthritis
Søren Andreas Just, MD, PhD: Developing AI to Mitigate Rheumatologist Shortages for Disease Assessment
Shreena K. Gandhi, MBBS: Recognizing Fibromyalgia as a Continuous Variable, Trait Diagnosis
Reducing Treatment Burden of Pegloticase for Uncontrolled Gout, with Orrin Troum, MD
Exploring CAR T-cell Therapy for Rheumatic/Autoimmune Diseases With Georg Schett, MD
John Stone, MD, MPH: Inebilizumab Efficacious for IgG4-Related Disease in MITIGATE Study
Uncovering the Role of COVID-19 in Rheumatic Disease, with Leonard Calabrese, DO
Comparing Treatment Options for Psoriatic Arthritis with Philip Mease, MD
Related Content
Megan Clowse, MD, MPH: Improving Disease and Reducing Corticosteroids in SLE With DZP
November 21st 2024

Megan Clowse, MD, MPH: Improving Disease and Reducing Corticosteroids in SLE With DZP

Victoria Johnson
Emerging Agents in the Treatment of Rheumatic Diseases
October 2nd 2023

Emerging Agents in the Treatment of Rheumatic Diseases

Nehad Soloman, MD, FACR Andrew Sharobeem, DO, FACR Philip J. Mease, MD
Philip Conaghan, MBBS, PhD, director, National Institute for Health & Care Research Leeds Biomedical Research Centre, and professor, Musculoskeletal Medicine, University of Leeds
November 20th 2024

LEVI-04 Improved Outcomes in Knee Osteoarthritis Compared With Placebo

Victoria Johnson
Challenges with Step Therapy Protocols in Treating Rheumatoid Arthritis
August 31st 2023

Challenges with Step Therapy Protocols in Treating Rheumatoid Arthritis

Nehad Soloman, MD, FACR Andrew Sharobeem, DO, FACR John B. Boone, MD, FACR Madelaine Feldman MD, FACR
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
November 19th 2024

Vagus Nerve Stimulation Yields Responses in Refractory Rheumatoid Arthritis

Victoria Johnson
Hermine Brunner, MD, MDc, MBA, Director, Division of Rheumatology, and professor, Department of Pediatrics, Cincinnati Children’s
November 18th 2024

Tofacitinib Not Superior to Placebo in Systemic Juvenile Arthritis Double-Blind Trial

Victoria Johnson
© 2024 MJH Life Sciences

All rights reserved.